Press Release

Zetagen Announces the Appointment of Debasish (Debu) Tripathy M.D. to its Advisory Board

18 March 2024
  • Dr. Tripathy is Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
  • A highly regarded, global leader and researcher in breast cancer treatment, Dr. Tripathy has led clinical trials of new biologic therapies targeting HER2 and CDKs, improving patient survival.
  • Zetagen is presently developing ZetaMet™ (zetaX003), a first-of-its kind molecular pathway in Phase 2a clinical trial for treatment of metastatic breast cancer lesions to bone as part of advanced stage cancer therapy.

Syracuse, New York, March 18, 2024 – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for the treatment of metastatic and primary cancers in bone and soft tissue organs, today announced the appointment of Debasish (Debu) Tripathy, MD to its advisory board. Dr. Tripathy is Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

“We are both pleased and honored to have Dr. Tripathy join our board of advisors at such meaningful moment in the expansion of Zetagen’s oncology pipeline,” said Joe C. Loy, CEO of Zetagen. “Dr. Tripathy’s expertise and proven track record of success in developing novel therapeutics for the treatment of breast cancer will be valued as we advance our novel therapy, ZetaMet™ and other oncologic candidates through clinical development. We look forward to working with and learning from him.”

Dr. Tripathy has led pivotal clinical trials supporting the approval of biological therapies for breast cancer patients, specifically targeting the HER2 oncogene and cyclin-dependent kinases (CDKs), both of which demonstrated improved patient survival. He has published a significant volume of original and landmark research in the field of breast cancer. Dr. Tripathy’s research focuses on assessing and developing novel therapeutics in breast cancer, specifically those targeting sensitivity and resistance mechanisms to growth factors, endocrine modulators, and cell cycle control pathways. He also evaluates biomarkers which predict sensitivity and resistance.

Dr. Tripathy received his medical degree from Duke University School of Medicine. He completed his residency at Duke University and fellowship at the Cancer Research Institute at the University of California, San Francisco. He has been Professor and Chairman of Breast Medical Oncology at MD Anderson Cancer Center since 2014.

All News

ZetaMet™ (Zeta-BC-003)

ZetaMet™ (Zeta-BC-003) is a synthetic, small molecule delivered via a proprietary controlled release carrier being developed to resolve metastatic bone lesions, inhibiting pain while regenerating bone, with the potential to increase survival rates.   Zetagen has discovered a new mechanism of action (MOA) for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions.  ZetaMet™ (Zeta-BC-003) was granted FDA Breakthrough Designation and is in Phase 2a clinical trial for treatment of metastatic breast cancer lesions to bone as part of advanced stage cancer therapy.

About zetagen Therapeutics

Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for metastatic and primary cancers to bone and other organs.

The company's pipeline encompasses several oncological candidates targeting metastatic and primary cancers for breast, lung, brain, prostate, and sarcomas with such drugs as ZetaMet™ (Zeta-BC-003), ZetaMet-P™ (Zeta-PC-004) and ZetaMAST™ (Zeta-MBC-005).

Forward-Looking Statements

This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Source: Zetagen Therapeutics, Inc.
Source: Zetagen Therapeutics, Inc.
SUNY Biotech Accelerator
841 E Fayette Street, Suite 1100
Syracuse, NY 13210
Investor Inquiries:
Zetagen Therapeutics, Inc.

Media Inquiries:
Mog & Springer Communications on Behalf of Zetagen Therapeutics, Inc.
Elizabeth Harness, Principal
Email: elizabeth.harness@mogandspringer.com
Phone: +1-585-435-7379